Small Intestinal Bacterial Overgrowth: A Primary Care Review

Mayo Clinic Proceedings

Volumn 91, Issue 12, 2016, Pages 1828-1833

  Krajicek, Edward J ^a   Hansel, Stephanie L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; METRONIDAZOLE; NEOMYCIN; RIFAXIMIN; TETRACYCLINE; VITAMIN K GROUP; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ALPHA TOCOPHEROL DEFICIENCY; ANTIBIOTIC RESISTANCE; BACTERIAL METABOLISM; BACTERIAL OVERGROWTH; BIOAVAILABILITY; BLOATING; BREATH ANALYSIS; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DYSBIOSIS; FLATULENCE; HUMAN; IRRITABLE COLON; LIMIT OF QUANTITATION; MACROCYTIC ANEMIA; MALNUTRITION; METABOLIC BONE DISEASE; MICROCYTIC ANEMIA; POLYNEUROPATHY; RETINOL DEFICIENCY; REVIEW; RISK FACTOR; SMALL INTESTINAL BACTERIAL OVERGROWTH; STEATORRHEA; VITAMIN D DEFICIENCY; WEIGHT REDUCTION; BACTERIAL INFECTION; ENTEROPATHY; FEMALE; GASTROINTESTINAL TRACT; MALE; MICROBIOLOGY; SMALL INTESTINE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEMALE; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL DISEASES; INTESTINE, SMALL; MALE;

EID: 85002814018     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2016.07.025     Document Type: Review

References (30)

1. 1 Peery, A.F., Dellon, E.S., Lund, J., et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143:5 (2012), 1179–1187.
2. 2 Miazga, A., Osinski, M., Cichy, W., Zaba, R., Current views on the etiopathogenesis, clinical manifestation, diagnostics, treatment and correlation with other nosological entities of SIBO. Adv Med Sci 60:1 (2015), 118–124.
3. 3 Neale, G., Gompertz, D., Schonsby, H., Tabaqchali, S., Booth, C.C., The metabolic and nutritional consequences of bacterial overgrowth in the small intestine. Am J Clin Nutr 25:12 (1972), 1409–1417.
4. 4 Dukowicz, A.C., Lacy, B.E., Levine, G.M., Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y) 3:2 (2007), 112–122.
5. 5 Khoshini, R., Dai, S.C., Lezcano, S., Pimentel, M., A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 53:6 (2008), 1443–1454.
6. 6 Sachdev, A.H., Pimentel, M., Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chronic Dis 4:5 (2013), 223–231.
7. 7 Sachdev, A.H., Pimentel, M., Antibiotics for irritable bowel syndrome: rationale and current evidence. Curr Gastroenterol Rep 14:5 (2012), 439–445.
8. 8 Bures, J., Cyrany, J., Kohoutova, D., et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 16:24 (2010), 2978–2990.
9. 9 Petrone, P., Sarkisyan, G., Fernandez, M., et al. Small intestinal bacterial overgrowth in patients with lower gastrointestinal symptoms and a history of previous abdominal surgery. Arch Surg 146:4 (2011), 444–447.
10. 10 Jacobs, C., Coss Adame, E., Attaluri, A., Valestin, J., Rao, S.S., Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther 37:11 (2013), 1103–1111.
11. 11 Barboza, J.L., Okun, M.S., Moshiree, B., The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease. Expert Opin Pharmacother 16:16 (2015), 2449–2464.
12. 12 Lauritano, E.C., Bilotta, A.L., Gabrielli, M., et al. Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab 92:11 (2007), 4180–4184.
13. 13 Lo, W.K., Chan, W.W., Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol 11:5 (2013), 483–490.
14. 14 Husebye, E., Skar, V., Hoverstad, T., Melby, K., Fasting hypochlorhydria with gram positive gastric flora is highly prevalent in healthy old people. Gut 33:10 (1992), 1331–1337.
15. 15 Sabate, J.M., Jouet, P., Harnois, F., et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 18:4 (2008), 371–377.
16. 16 Grace, E., Shaw, C., Whelan, K., Andreyev, H.J.N., Review article: small intestinal bacterial overgrowth: prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 38:7 (2013), 674–688.
17. 17 Di Stefano, M., Veneto, G., Malservisi, S., Corazza, G.R., Small intestine bacterial overgrowth and metabolic bone disease. Dig Dis Sci 46:5 (2001), 1077–1082.
18. 18 Baker, J.C., Saad, W.J., Common gastrointestinal symptoms do not predict the results of glucose breath testing in the evaluation of suspected small intestinal bacterial overgrowth. Am J Gastroenterol(110), 2015, S1004.
19. 19 Ringel-Kulka, T., Choi, C.H., Temas, D., et al. Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome. Am J Gastroenterol 110:9 (2015), 1339–1346.
20. 20 Levitt, M.D., Bond, J.H. Jr., Volume, composition, and source of intestinal gas. Gastroenterology 59:6 (1970), 921–929.
21. 21 Rezaie, A., Pimentel, M., Rao, S.S., How to test and treat small intestinal bacterial overgrowth: an evidence-based approach. Curr Gastroenterol Rep, 18(2), 2016, 8.
22. 22 Erdogan, A., Lee, Y.Y., Badger, C., Hall, P., O'Banion, M.E., Rao, S.S., What is the optimal threshold for an increase in hydrogen and methane levels with glucose breath test (GBT) for detection of small intestinal bacterial overgrowth (SIBO)?. Gastroenterology, 146(5), 2014, S532.
23. 23 Erdogan, A., Rao, S.S.C., Gulley, D., Jacobs, C., Lee, Y.Y., Badger, C., Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil 27:4 (2015), 481–489.
24. 24 Lin, E.C., Massey, B.T., Scintigraphy demonstrates high rate of false-positive results from glucose breath tests for small bowel bacterial overgrowth. Clin Gastroenterol Hepatol 14:2 (2016), 203–208.
25. 25 Posserud, I., Stotzer, P.O., Bjornsson, E.S., Abrahamsson, H., Simren, M., Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56:6 (2007), 802–808.
26. 26 Gasbarrini, A., Corazza, G.R., Gasbarrini, G., et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther 29:suppl 1 (2009), 1–49.
27. 27 Sellin, J.H., A breath of fresh air. Clin Gastroenterol Hepatol 14:2 (2016), 209–211.
28. 28 Shah, S.C., Day, L.W., Somsouk, M., Sewell, J.L., Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther 38:8 (2013), 925–934.
29. 29 Pimentel, M., Constantino, T., Kong, Y., Bajwa, M., Rezaei, A., Park, S., A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci 49:1 (2004), 73–77.
30. 30 Pimentel, M., Morales, W., Lezcano, S., Sun-Chuan, D., Low, K., Yang, J., Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y) 5:6 (2009), 435–442.